CagriSema combines cagrilintide (amylin analogue) with semaglutide (GLP-1S), pairing two distinct appetite and glucose-regulating mechanisms in a single formulation. Semaglutide activates GLP-1 receptors to enhance insulin secretion, slow gastric emptying, and reduce caloric intake, while cagrilintide contributes via the amylin pathway to further modulate satiety and postprandial glucagon. The combination has been studied in clinical research for additive effects on weight reduction beyond what either compound achieves alone.